RE:RE:RE:Tilray is at $17 a share time to buy as much tilray-aprhiaBigginvestor wrote: Craiger02 wrote: Just a helpful suggestion, but I'd be looking at buying Curaleaf before Tilray. 3 billion cap vs 12 billion. Great leadership and with the emmac acquisition, will dominate Europe. Tilray currently has no ability to sell in the US, while cura has over 100 locations and is grandfathered into NY legalization.
no tilray merged with aprhia and tilray has huge market in Germany and Europe apriha has market in USA with a beer company so the combine company with beer will be huge compare to weed .they looking at $1 billion in revenue with the two mergers .
You are correct on portions of the above. I'm not comparing to canopy though. I'm speaking of Curaleaf vs tilray (currently trading around the same $ amount).
although Tilray has an entry point into the US via beverage company, they currently do have any cultivation or retail setup. That's why I suggested Curaleaf which already operates over 100 locations. Expansion once safe act passes, will cost Tilray a huge multiple versus what is currently being paid. I think they're just too far behind right now to catch up starting from scratch. With NY, they will not be able to enter in all facets either with that way they structured legalization. As they currently have no licenses for medical, they will not be able to grow, distribute and retail themselves. Just some friendly advice. Hopefully whichever direction you choose works out well for you